Becton Dickinson Return on Investment 2010-2024 | BDX
Current and historical return on investment (ROI) values for Becton Dickinson (BDX) over the last 10 years.
Becton Dickinson ROI - Return on Investment Historical Data |
Date |
TTM Net Income |
LT Investments & Debt |
Return on Investment |
2024-06-30 |
$2.13B |
$44.00B |
5.13% |
2024-03-31 |
$2.07B |
$41.64B |
5.10% |
2023-12-31 |
$1.96B |
$39.43B |
4.83% |
2023-09-30 |
$2.11B |
$40.53B |
5.19% |
2023-06-30 |
$2.25B |
$40.86B |
5.57% |
2023-03-31 |
$2.24B |
$41.70B |
5.57% |
2022-12-31 |
$2.18B |
$39.74B |
5.40% |
2022-09-30 |
$2.28B |
$39.17B |
5.64% |
2022-06-30 |
$1.88B |
$40.18B |
4.59% |
2022-03-31 |
$1.83B |
$42.11B |
4.49% |
2021-12-31 |
$1.70B |
$40.52B |
4.15% |
2021-09-30 |
$2.25B |
$40.79B |
5.49% |
2021-06-30 |
$1.85B |
$39.84B |
4.51% |
2021-03-31 |
$1.72B |
$42.54B |
4.15% |
2020-12-31 |
$1.65B |
$40.75B |
4.12% |
2020-09-30 |
$0.91B |
$40.99B |
2.31% |
2020-06-30 |
$1.34B |
$41.11B |
3.43% |
2020-03-31 |
$1.61B |
$37.76B |
4.16% |
2019-12-31 |
$1.38B |
$38.15B |
3.53% |
2019-09-30 |
$1.76B |
$39.16B |
4.49% |
2019-06-30 |
$2.22B |
$39.51B |
5.65% |
2019-03-31 |
$2.11B |
$38.87B |
5.28% |
2018-12-31 |
$2.16B |
$39.22B |
5.25% |
2018-09-30 |
$1.51B |
$39.89B |
3.58% |
2018-06-30 |
$1.42B |
$41.71B |
3.55% |
2018-03-31 |
$0.69B |
$43.74B |
1.84% |
2017-12-31 |
$0.95B |
$43.34B |
3.08% |
2017-09-30 |
$1.52B |
$31.62B |
6.31% |
2017-06-30 |
$1.13B |
$31.15B |
5.44% |
2017-03-31 |
$1.87B |
$17.05B |
10.61% |
2016-12-31 |
$1.89B |
$16.63B |
10.50% |
2016-09-30 |
$1.43B |
$18.18B |
7.79% |
2016-06-30 |
$1.63B |
$18.59B |
8.83% |
2016-03-31 |
$1.25B |
$18.53B |
6.77% |
2015-12-31 |
$1.08B |
$18.08B |
5.78% |
2015-09-30 |
$1.07B |
$18.53B |
6.01% |
2015-06-30 |
$1.18B |
$18.62B |
7.65% |
2015-03-31 |
$1.49B |
$19.29B |
11.40% |
2014-12-31 |
$1.58B |
$15.01B |
15.00% |
2014-09-30 |
$1.61B |
$8.82B |
17.90% |
2014-06-30 |
$1.28B |
$9.15B |
14.29% |
2014-03-31 |
$1.24B |
$9.08B |
14.10% |
2013-12-31 |
$1.24B |
$8.84B |
14.40% |
2013-09-30 |
$1.26B |
$8.81B |
14.82% |
2013-06-30 |
$1.57B |
$8.48B |
19.02% |
2013-03-31 |
$1.61B |
$8.35B |
19.84% |
2012-12-31 |
$1.61B |
$8.23B |
19.81% |
2012-09-30 |
$1.56B |
$7.90B |
18.87% |
2012-06-30 |
$1.53B |
$8.00B |
18.90% |
2012-03-31 |
$1.53B |
$8.44B |
19.00% |
2011-12-31 |
$1.59B |
$8.70B |
20.24% |
2011-09-30 |
$1.66B |
$7.31B |
22.16% |
2011-06-30 |
$1.62B |
$7.78B |
21.79% |
2011-03-31 |
$1.59B |
$7.58B |
22.33% |
2010-12-31 |
$1.57B |
$7.36B |
22.71% |
2010-09-30 |
$1.58B |
$6.93B |
23.48% |
2010-06-30 |
$1.65B |
$6.65B |
24.69% |
2010-03-31 |
$1.66B |
$6.64B |
24.78% |
2009-12-31 |
$1.60B |
$6.75B |
25.01% |
Sector |
Industry |
Market Cap |
Revenue |
Medical |
Medical & Dental Supplies |
$69.388B |
$19.372B |
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|